Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duyiwei refers to a traditional Chinese herbal medicine derived from the plant Lamiophlomis rotata. It is widely used in China as an orally available Tibetan analgesic and is formulated in various dosage forms such as capsules and cataplasms. The primary active constituent identified is shanzhiside methylester (SM), an iridoid glycoside that acts as a small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor. Mechanistically, SM reduces neuropathic pain by activating spinal GLP-1 receptors, which stimulates microglial β-endorphin expression via p38 mitogen-activated protein kinase (MAPK) signaling pathways. This cascade results in analgesic and anti-inflammatory effects without inducing tolerance or cross-tolerance with opioids like morphine or β-endorphin. Clinically, Duyiwei has been approved for use in China for indications such as hemorrhage and uterine hemorrhage; it has also been studied for knee osteoarthritis and gingivitis[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on duyiwei.